PROVEN REVISION FEMORAL AND PROVEN REVISION TIBIAL INSERT

K031901 · Stelkast Company · JWH · Oct 10, 2003 · Orthopedic

Device Facts

Record IDK031901
Device NamePROVEN REVISION FEMORAL AND PROVEN REVISION TIBIAL INSERT
ApplicantStelkast Company
Product CodeJWH · Orthopedic
Decision DateOct 10, 2003
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Intended Use

1. Total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems. 2. Revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present. 3. For cemented use only.

Device Story

Stelkast Proven Cemented, Semi-Constrained Total Knee System is a prosthetic implant for total knee arthroplasty. Device replaces damaged joint surfaces in patients with degenerative joint disease or failed prior reconstructions. System is intended for cemented fixation only. Used by orthopedic surgeons in hospital operating rooms. Provides mechanical stability and joint articulation to restore function and reduce pain associated with knee joint pathology.

Clinical Evidence

No clinical data provided; substantial equivalence based on design and technological characteristics.

Technological Characteristics

Semi-constrained cemented knee prosthesis; metal/polymer construction. Designed for patellofemorotibial replacement. Class II device per 21 CFR 888.3560.

Indications for Use

Indicated for patients requiring total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis, post-traumatic degenerative conditions, or revision of failed reconstructions with adequate bone stock and soft tissue integrity. For cemented use only.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, consisting of a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus. OCT 1 0 2003 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Donald A. Stevens President Stelkast Company 200 Hidden Valley Road McMurray, Pennsylvania 15317 Re: K031901 Trade/Device Name: Stelkast Proven Cemented, Semi-Constrained Total Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis Regulatory Class: II Product Code: JWH Dated: September 30, 2003 Received: October 1, 2003 Dear Mr. Stevens: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {1}------------------------------------------------ Page 2 - Mr. Donald A. Stevens This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, R. Mark M Millherson elia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## 510(K) Number (if known): ## StelKast Proven Cemented, Semi-Constrained Device Name: Total Knee System K980276 ## Indications For Use: - 1. Total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems. - 2. Revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present. - 3. For cemented use only. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) | (Division Sign-Off) | | |-----------------------------------------------------------|---------| | Division of General, Restorative and Neurological Devices | | | 510(k) Number | K031901 | Prescription Use ______________________________________________________________________________________________________________________________________________________________________________ (Per 21 CFR 801.109) OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%